Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT00043082
First received: August 5, 2002
Last updated: June 11, 2012
Last verified: June 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2011
  Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Publications:
Alberts DS, Liu PY, Wilczynski S, et al.: Phase III randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: Southwest Oncology Group protocol S0200. [Abstract] J Clin Oncol 25 (Suppl 18): A-5551, 286s, 2007.